We are pleased to appoint Dr. Debra Odink to President & CDO, and Dr. Shi Yin Foo to our Board. Both individuals bring impressive depth of development and company building expertise, which will be crucial as Thryv moves into clinical trials later this month.

We are excited to announce the evolution of our portfolio to include treatments for resistant and rare cancers. The new name, Thryv Therapeutics, embodies our commitment to relentlessly pursue therapies which provide lifelong benefits to patients, families, doctors, nurses and stakeholders.

Dr. Campeau will collaborate with Dr. McDonnell and his research team at Duke University to evaluate SGK1 inhibitors as potential treatments for people with breast and prostate cancer.

A major objective after our Series A financing, has been to enrich our Board with experienced, respected and highly accomplished drug development executives as we advance our clinical programs.

LQTT has completed US$19 million Series A financing led by Amplitude Ventures and included new investments from existing investors. We’re advancing a series of in-licensed compounds discovered and developed by Sanofi S.A. that inhibit SGK1.

Amplitude Ventures exceeded their CAD$200M raise target and attracted investment from across the country and internationally. Amplitude is an early seed investor of LQTT.

Marc-Olivier Sirard, CPA, senior investment advisor at Fonds de solidarité FTQ, and Dr. Saumya Das, PhD, MD, Director of the Resynchronization and Advanced Cardiac Therapeutics Program at Massachusetts General Hospital, join our board of directors.

Research collaboration with the Mayo Clinic in Rochester, Minnesota to evaluate novel pharmacologic treatments for LQTS, an arrhythmia associated with a prolonged QT interval that can cause sudden death.

LQT Therapeutics raised up to C$1.8M seed funding led by Fonds de solidarité FTQ and other founding investors. Our aim is to develop a series of preclinical compounds as new treatment options for Long QT Syndrome and other arrhythmias.